Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? (Q38242271)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Evelien Smits

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Marta Castiglia

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Giovanni Sortino

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Francesco Passiglia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Giuseppe Bronte

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Antonio Russo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Edgardo S Santos

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Annelies Janssens

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Patrick Pauwels

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Luis Raez

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

language of work or name

1 reference

22 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

13 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

1173-1187

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25148289%20AND%20SRC:MED&resulttype=core&format=json

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

13 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Cancer immunoediting by the innate immune system in the absence of adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Immune surveillance of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Emerging therapeutic targets in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

GM-CSF gene-transduced tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

MUC1 immunobiology: from discovery to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

L-BLP25: a peptide vaccine strategy in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

EGFR pathway in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Gangliosides in cell recognition and membrane protein regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Role of PD-1 in Regulating T-Cell Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Programmed death-ligand 1 (PD-L1) expression in various tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952287